BPC-157 regulatory status
Current status of BPC-157 in the United States: HHS interim policy (draft). In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of BPC-157?
- FDA and compounding
- BPC-157 is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157 when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous, intramuscular, oral, or topical), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. Oral forms also need documentation that the formulation is adequately absorbed by mouth in humans. The draft policy is not an FDA approval, does not add BPC-157 to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.
- WADA
- WADA prohibited
- Access path
- Compounded access under HHS's draft policy (announced October 28, 2026): HHS says it does not intend to take enforcement action when a state-licensed pharmacy or licensed physician compounds single-ingredient BPC-157 by injection under the skin or into muscle, by mouth, or on the skin on a patient-specific prescription, under strict quality and reporting conditions. The policy is a draft, is not binding, and HHS may revisit it. Blends and stacks are not covered, and state law still applies.
- Not available as an FDA approved product.
- Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.
Full BPC-157 page: evidence, dosing in the literature, and sources
Is BPC-157 FDA approved or legal? Questions and answers
Is BPC-157 FDA approved?
No. BPC-157 is not an FDA approved drug for any use, in any form. FDA placed it on the 503A Category 2 list in 2023, and FDA's list dated April 22, 2026 shows the nomination as withdrawn. At the July 23, 2026 compounding advisory committee meeting, FDA's drug center (CDER) recommended against listing it and the committee voted in favor (HHS policy, Appendix B). A committee vote is advisory and is not an approval. HHS's October 28, 2026 draft enforcement discretion policy is not an approval either: HHS only says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient BPC-157 for a named patient on a prescription, under strict conditions. Even a final listing would only let a 503A pharmacy compound it for a named patient on a prescription; it would not make BPC-157 an approved drug. [1] [2] [3] [4] [5]
What is the FDA status of BPC-157 in 2026?
HHS interim policy (draft). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157 as a single-ingredient product by an allowed route (subcutaneous, intramuscular, oral, or topical), on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. It is not an FDA approval or a 503A bulks listing, it is not binding, and HHS may revisit it; comments are open through November 13, 2026. Before that, BPC-157 was in 503A Category 2 from September 2023 until April 22, 2026, when its nomination was withdrawn, and at the July 23, 2026 advisory committee meeting FDA's drug center (CDER) recommended against listing it while the committee voted in favor (HHS policy, Appendix B). Blends and stacks are not covered. The timeline below records each step with its source. [1] [2] [4] [5]
Is BPC-157 legal?
There is still no FDA approved BPC-157. Under HHS's October 28, 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a state-licensed pharmacy or licensed physician that compounds single-ingredient BPC-157 by injection under the skin or into muscle, by mouth, or on the skin on a patient-specific prescription, if every quality and reporting condition is met. The policy is a draft, is not binding, and HHS may revisit it; it is not an approval and does not add BPC-157 to the 503A bulks list. Blends such as BPC-157 with TB-500 are not covered. State law still applies, and products labeled research use only are still unapproved drugs when sold for human use and are not verified for purity. [3] [4] [5] [6]
Why does FDA say BPC-157 is not approved for human use?
Because no BPC-157 product has ever been approved, anything sold for people is an unapproved drug. In 2023 FDA placed BPC-157 in 503A Category 2, its list of bulk substances that may present significant safety risks, and FDA's list dated April 22, 2026 now shows the nomination as withdrawn by its nominator. Withdrawal is not an FDA safety finding or an approval, and it does not put BPC-157 on the 503A bulks list; only a final FDA rule can do that. [1] [3]
Is BPC-157 banned in sports?
Yes. BPC-157 is prohibited at all times under section S0 (non-approved substances) of the WADA Prohibited List, which has named it as an example since the 2022 list. Athletes subject to testing should not use it, and no FDA compounding decision would change its WADA status. [7]
How has the status of BPC-157 changed over time?
- HHS
HHS draft policy lets licensed pharmacies compound six peptides without enforcement action
HHS Secretary Robert F. Kennedy Jr. announced a draft enforcement discretion policy (FR Doc. 2026-22192, filed October 28 and published in the Federal Register on October 30, 2026). HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157, epitalon, KPV, MOTS-c, semax, or TB-500, if the product contains a single active ingredient, uses an allowed route, is made from an FDA-registered manufacturer's substance with a tested certificate of analysis, carries a patient-specific prescription, and serious adverse events are reported to FDA. It is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Comments are open through November 13, 2026 on Docket HHS-OASH-2026-0496.
- WADA
WADA publishes the 2027 Prohibited List
WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.
- PCAC
FDA advisory committee reviews six peptides; FDA's briefing recommends against listing
At its July 23 to 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon for the 503A bulks list. FDA's own briefing slides proposed not adding any of them. The committee voted in favor of listing all six, as HHS confirmed in its October 2026 peptide policy. The committee is advisory, and FDA proposed no rule, so none of the six was added to the 503A bulks list.
Regulatory: Nomination withdrawnSource: FDA: Pharmacy Compounding Advisory Committee, July 23, 2026, FDA presentation slides - FDA
FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2
FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.
- WADA
WADA 2026 Prohibited List takes effect
The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.
- WADA
WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times
The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 and its derivatives, including TB-500, and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.
- FDA
FDA places a batch of nominated peptides in 503A Category 2
In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.
- WADA
WADA 2022 Prohibited List adds BPC-157 as an S0 example
The 2022 WADA Prohibited List took effect on January 1, 2022 and named BPC-157 as an example of a non-approved substance under section S0, making it prohibited at all times for athletes under the World Anti-Doping Code.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for BPC-157 and the source of each dated event.
- [1]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (503A Category 2 list and nominated but withdrawn substances, current as of April 22, 2026)FDA, 2026
- [2]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [3]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [4]HHS: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (draft), with Appendix A (covered peptides) and Appendix B (identity, routes, and committee history)2026
- [5]Federal Register notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192 (Docket HHS-OASH-2026-0496)Federal Register, 2026
- [6]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [7]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [8]WADA 2027 Prohibited ListWADA, 2026
- [9]FDA: Pharmacy Compounding Advisory Committee, July 23, 2026, FDA presentation slidesFDA, 2026
From the blog
- BPC-157 and cancer: what the evidence shows
Does BPC-157 cause cancer or feed tumors? The concern is theoretical, based on blood vessel growth in animal studies. No human study has assessed it, and FDA found no carcinogenicity data.
- BPC-157 before and after: reviews, results, and what controlled studies show
BPC-157 reviews and before and after stories are everywhere. Controlled results exist only in rats. What the animal healing timelines show, what the human pilots found, and why anecdotes mislead.
- BPC-157 capsules and pills: what oral BPC-157 was tested for, and what is missing
BPC-157 capsules and pills rest on rat gut, ligament, and fistula studies. No study has measured how much a capsule absorbs in people, and the two registered oral studies have posted no results.
- BPC-157 for gut health: the animal evidence and the missing human trials
BPC-157 healed ulcers, colitis, fistulas, and short bowel in rats. No human gut trial has published results. What the GI studies found, what is missing, and what has human evidence.
- BPC-157 human studies: every published report and registered clinical trial
Every published BPC-157 human report, with sample size and limits, plus every registered clinical trial on ClinicalTrials.gov. About 30 people, no control groups, and no randomized results yet.
- BPC-157 nasal spray: what is and is not known about intranasal use
No published study has given BPC-157 as a nasal spray to animals or people. What the one nose-related rat study tested, what a nasal peptide must prove, and its legal status.